1. High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2.
- Author
-
Shahrokh S, Baradaran Ghavami S, Asadzadeh Aghdaei H, Parigi TL, Farmani M, Danese S, Ebrahimi Daryani N, Vossoughinia H, Balaii H, Alborzi F, Khoramjoo SM, Khanabadi B, Seyed Salehi A, Bastani A, Sharifi M, Safari MT, Malekpour H, Sherkat G, Saberafsharian M, Miri MB, Moosavi SH, Anaraki F, Nazemalhosseini-Mojarad E, Mohebbi SR, Shojaie S, Pourhoseingholi MA, and Zali MR
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Retrospective Studies, Cross-Sectional Studies, Prevalence, Iran epidemiology, Interferon-alpha blood, Peptidyl-Dipeptidase A blood, Immunoglobulin M blood, Antibodies, Viral blood, Immunoglobulin G blood, COVID-19 epidemiology, COVID-19 blood, Angiotensin-Converting Enzyme 2 metabolism, Inflammatory Bowel Diseases blood, Inflammatory Bowel Diseases epidemiology, SARS-CoV-2
- Abstract
Context: Patients with inflammatory bowel disease (IBD) were found to have the higher intestinal expression of Angiotensin-Converting Enzyme2 (ACE2) that could consequently increase susceptibility to COVID-19 infection. Objective: This study reports the outcomes of COVID-19 infection in a large cohort of IBD patients. We compare levels of serum ACE and IFN-α between COVID19 patients with and without IBD. We performed a cross-sectional retrospective multicenter study. Methods: We enrolled patients with IBD screened for SARS-COV-2 in six medical centres in Iran from June to November 2020. The blood samples were drawn to measure COVID-19 IgM and IgG, and serum levels of sACE2, sACE1, and interferon-α, regardless of suspicious symptoms have done the molecular test. Results: A total of 534 IBD patients were included in the study. Of these, 109 (20.0%) cases had detectable IgG and IgM against SARS-CoV-2. sACE2 levels were higher in IBD patients than controls, whereas ACE1and IFN-α levels were similar among groups.
- Published
- 2024
- Full Text
- View/download PDF